Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT03434379 Completed - Clinical trials for Carcinoma, Hepatocellular

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

IMbrave150
Start date: March 15, 2018
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have received no prior systemic treatment.

NCT ID: NCT03433027 Completed - Clinical trials for Head and Neck Squamous Cell Carcinoma

A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Start date: March 15, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and efficacy of intratumoral injections with an Epidermal Growth Factor Receptor (EGFR) AntiSense DNA (BB-401) in patients with metastatic/recurrent HNSCC.

NCT ID: NCT03430895 Completed - Clinical trials for Metastatic Bladder Cancer

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Start date: January 31, 2018
Phase: Phase 2
Study type: Interventional

This study is being done test to test the safety and effectiveness of durvalumab combined with tremelimumab in patients who have a rare form of cancer of the urinary tract.

NCT ID: NCT03430843 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma (ESCC)

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Start date: January 26, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.

NCT ID: NCT03430635 Completed - Clinical trials for Hepatocellular Carcinoma

Role of Choline PET/CT in Predicting Survival in Patients With Hepatocellular Carcinoma

Start date: January 1, 2010
Phase: N/A
Study type: Observational

¹¹C-choline positron emission tomography/computed tomography (PET/CT) has been used in patients with some types of solid cancers, but few data are available in patients undergoing hepatectomy for hepatocellular carcinoma (HCC). The aim of this study was to analyze the prognostic value of metabolic imaging data by using ¹¹C-choline PET/CT in patients with HCC before hepatectomy.

NCT ID: NCT03429868 Completed - Clinical trials for Nasopharyngeal Carcinoma

PET and MRI in Prognosis Prediction of NPC

Start date: August 1, 2015
Phase: N/A
Study type: Interventional

Nasopharyngeal carcinoma (NPC) differs from other head and neck malignancies terms of its epidemiology, pathology, and treatment outcome. Integrated PET/MRI is a new imaging modality, which can simultaneously acquire PET and MRI images. Considering the lack of reports on the use of hybrid PET/MRI systems in prognosis prediction in NPC, the investigators conduct this prospective study to investigate the roles of integrated PET/MRI parameters for predicting treatment outcome and prognosis in patients with NPC.

NCT ID: NCT03428217 Completed - Clinical trials for Metastatic Renal Cell Carcinoma

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

CANTATA
Start date: April 24, 2018
Phase: Phase 2
Study type: Interventional

Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib (Pbo-Cabo) for advanced or metastatic clear-cell RCC (ccRCC).

NCT ID: NCT03427476 Completed - Clinical trials for Renal Cell Carcinoma

CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma

Start date: January 1, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test a novel diagnostic PET imaging agent for safety and biodistribution. The agent binds PSMA and is designed to detect Prostate Specific Membrane Antigen expressing tumors, such as has been described for some renal cell carcinoma tumors.

NCT ID: NCT03427359 Completed - Clinical trials for Nasopharyngeal Carcinoma

Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

Start date: January 22, 2015
Phase: Phase 2
Study type: Interventional

To prospectively evaluate the short-term efficacy and toxicity of induction chemotherapy with cisplatin and capecitabine followed by concurrent chemoradiotherapy (CCRT) in the treatment of locally advanced nasopharyngeal carcinoma.

NCT ID: NCT03422536 Completed - Clinical trials for Head and Neck Cancer

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Start date: December 5, 2017
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well ficlatuzumab with or without cetuximab works in treating patients with head and neck squamous cell carcinoma that has come back or spread to other places in the body and resistant to cetuximab treatment. Monoclonal antibodies, such as ficlatuzumab and cetuximab, may block growth signals that lets a tumor cell survive and reproduce, and helps the immune system recognize and fight head and neck squamous cell carcinoma.